News | Radiopharmaceuticals and Tracers | July 16, 2019

NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility

Facility part of staged, dual production pathway plan to expand Mo-99 production and efficiency in parallel with RadioGenix System enhancements

NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility

July 16, 2019 – NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-99) processing facility in Beloit, Wis., with equipment installation currently underway. Establishing this processing facility is part of NorthStar’s staged development and dual processing pathway approach to expanding current capacity and efficiencies in Mo-99 production.

Domestically produced, non-uranium based Mo-99 is used in NorthStar’s RadioGenix System (technetium 99m generator). Commercially available and U.S. Food and Drug Administration (FDA)-approved, the RadioGenix System is a high-tech separation platform for processing non-uranium/non-highly enriched uranium based Mo-99 for production of the important medical radioisotope, technetium-99m (Tc-99m), the most widely used diagnostic imaging radioisotope.

Along with its partners at the University of Missouri Research Reactor (MURR), NorthStar is consistently providing domestic, non-uranium-based Mo-99 now and is actively planning for the future, according to the company. Upon appropriate licensure and FDA approval, the processing facility in Beloit will augment current processing at MURR, providing dual production hubs for Mo-99. The facility will house state-of-the-art Mo-99 dissolution and source vessel filling equipment, as well as support a quality control laboratory, an automated packaging line and an advanced molybdenum recycling complex.

NorthStar President and CEO Stephen Merrick said the new facility will enable the company to double production of RadioGenix System source vessels, which are used by radiopharmacies to product Tc-99m for physicians and their patients. 

In addition to the processing facility expansion, Merrick said NorthStar is working toward final validation of two state-of-the-art fill lines at its Columbia, Mo., facility that, pending expected FDA approval in 2019, will further substantially increase the number of Mo-99 source vessels that can be shipped to customers weekly.

Read the article "NorthStar Medical Radioisotopes Breaks Ground for New Facility in Beloit, Wis."

For more information: www.northstarnm.com

Related Content

FDA Clears Path for First Domestic Supply of Tc-99m Isotope

New Report Finds U.S. Supply of Critical Medical Isotope Vulnerable

Related Content

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can bee seen in this photo on either side of the patient bed. These can be rotated above the patient.

Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can be seen in this photo on either side of the patient bed. These can be rotated above the patient.

Feature | Nuclear Imaging | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — Philips Medical System is recalling the Forte Gamma Camera System due to the potential for the 660
 Phoenix’s fusion neutron generation technology.
News | Radiopharmaceuticals and Tracers | October 28, 2019
October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
A 3-D printed tungsten pre-clinical X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten pre-clinical X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | September 04, 2019 | By Steve Jeffery
In ...